• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝素诱导的血小板减少症发病机制的演变概念:诊断和治疗意义。

Evolving concepts of pathogenesis of heparin-induced thrombocytopenia: Diagnostic and therapeutic implications.

机构信息

Heamatology Department, New South Wales Health Pathology, Kogarah and Sutherland Campuses, Sydney, NSW, Australia.

Heamatolgy Department, St George and Sutherland Hospitals, Sydney, NSW, Australia.

出版信息

Int J Lab Hematol. 2020 Jun;42 Suppl 1:25-32. doi: 10.1111/ijlh.13223.

DOI:10.1111/ijlh.13223
PMID:32543064
Abstract

Heparin-induced thrombocytopenia (HIT) is an immune reaction to heparin. It often causes severe thrombosis which may lead to limb gangrene and thrombosis-associated death. The concept of its pathogenesis has been evolving during the past five decades. Initially, HIT was thought to be caused by disseminated intravascular coagulation. Later it became clear that HIT was mediated by an immune mechanism whereby an IgG antibody induced platelet aggregation, release of procoagulant materials and consequently thrombus formation. The antigen comprises Platelet Factor 4 (PF4) and heparin which have a tendency to form ultralarge complexes. The HIT immune response has atypical features. IgG antibody appears early without IgM precedence and lasts transiently. One explanation is that there is prior priming by bacterial infection. Another unique characteristic is that it is processed as if it is a particulate antigen involving complement activation and B cells. Antigen-presenting cells/monocytes are also involved but the role of T cells is controversial. Recent advances have provided new insights into the underlying mechanisms of HIT-related thrombosis. Previously, platelets were believed to play a central role; their activation and consequently the induction of blood coagulation was the basis of the hypercoagulability in HIT. More recently, several studies have provided clear evidence that neutrophil and NETosis, monocytes and endothelial cells contribute significantly to the thrombosis in HIT. These new insights may result in development of better diagnostic laboratory assays and more effective treatments for HIT.

摘要

肝素诱导的血小板减少症(HIT)是一种针对肝素的免疫反应。它常导致严重的血栓形成,可能导致肢体坏疽和与血栓相关的死亡。其发病机制的概念在过去五十年中一直在发展。最初,HIT 被认为是由弥漫性血管内凝血引起的。后来清楚的是,HIT 是由免疫机制介导的,其中 IgG 抗体诱导血小板聚集、释放促凝物质,进而导致血栓形成。抗原包括血小板因子 4(PF4)和肝素,它们有形成超大复合物的倾向。HIT 的免疫反应具有非典型特征。IgG 抗体在没有 IgM 前期的情况下早期出现,并持续短暂。一种解释是存在细菌感染的预先致敏。另一个独特的特征是,它被处理为似乎是一种涉及补体激活和 B 细胞的颗粒性抗原。抗原呈递细胞/单核细胞也参与其中,但 T 细胞的作用存在争议。最近的进展为 HIT 相关血栓形成的潜在机制提供了新的见解。以前,血小板被认为起着核心作用;它们的激活,进而血液凝固的诱导是 HIT 中高凝状态的基础。最近,几项研究提供了明确的证据,表明中性粒细胞和 NETosis、单核细胞和内皮细胞对 HIT 中的血栓形成有重要贡献。这些新的见解可能导致更好的诊断实验室检测方法和更有效的 HIT 治疗方法的发展。

相似文献

1
Evolving concepts of pathogenesis of heparin-induced thrombocytopenia: Diagnostic and therapeutic implications.肝素诱导的血小板减少症发病机制的演变概念:诊断和治疗意义。
Int J Lab Hematol. 2020 Jun;42 Suppl 1:25-32. doi: 10.1111/ijlh.13223.
2
Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia.中性粒细胞活化和 NETosis 是肝素诱导的血小板减少症中血栓形成的主要驱动因素。
Nat Commun. 2019 Mar 21;10(1):1322. doi: 10.1038/s41467-019-09160-7.
3
[Anti-heparin/platelet factor 4 antibodies and heparin-induced thrombocytopenia--review].[抗肝素/血小板第4因子抗体与肝素诱导的血小板减少症——综述]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Apr;16(2):457-60.
4
Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly.肝素诱导的血小板减少症:一种通过动态自身抗原组装/拆卸调节的自身免疫性疾病。
J Clin Apher. 2007 Feb;22(1):31-6. doi: 10.1002/jca.20109.
5
Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia.755例连续送检进行肝素诱导的血小板减少症诊断检测的患者样本中IgG、IgM和IgA类抗PF4/肝素抗体的发生率及临床意义。
Eur J Haematol. 2006 May;76(5):420-6. doi: 10.1111/j.1600-0609.2005.00621.x. Epub 2006 Feb 6.
6
Heparin-induced thrombocytopenia: a ten-year retrospective.肝素诱导的血小板减少症:十年回顾性研究
Annu Rev Med. 1999;50:129-47. doi: 10.1146/annurev.med.50.1.129.
7
Role of monocytes and endothelial cells in heparin-induced thrombocytopenia.单核细胞和内皮细胞在肝素诱导的血小板减少症中的作用。
Thromb Haemost. 2016 Oct 28;116(5):806-812. doi: 10.1160/TH16-02-0162. Epub 2016 Aug 4.
8
Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia.肝素诱导的血小板减少症患者中针对肝素-PF4复合物的IgA和/或IgM抗体的致病性
Br J Haematol. 1996 Mar;92(4):954-9. doi: 10.1046/j.1365-2141.1996.407945.x.
9
Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.肝素诱导的血小板减少症/血栓形成患者的抗体对与肝素复合或与内皮细胞结合的血小板因子4具有特异性。
J Clin Invest. 1994 Jan;93(1):81-8. doi: 10.1172/JCI116987.
10
HITlights: a career perspective on heparin-induced thrombocytopenia.HITlights:肝素诱导的血小板减少症的职业视角。
Am J Hematol. 2012 May;87 Suppl 1:S92-9. doi: 10.1002/ajh.23127. Epub 2012 Feb 24.

引用本文的文献

1
Anti-PF4 disorders: Pathogenesis, diagnosis and treatment.抗PF4相关疾病:发病机制、诊断与治疗
Br J Haematol. 2025 Jul 1. doi: 10.1111/bjh.20216.
2
Management of Heparin-Induced Thrombocytopenia: A Contemporary Review.肝素诱导的血小板减少症的管理:当代综述
J Clin Med. 2024 Aug 9;13(16):4686. doi: 10.3390/jcm13164686.
3
Proteomic profiling for biomarker discovery in heparin-induced thrombocytopenia.肝素诱导的血小板减少症生物标志物发现的蛋白质组学分析。
Blood Adv. 2024 Jun 11;8(11):2825-2834. doi: 10.1182/bloodadvances.2024012782.
4
Cloned antibodies from patients with HIT provide new clues to HIT pathogenesis.从 HIT 患者中克隆的抗体为 HIT 发病机制提供了新的线索。
Blood. 2023 Mar 2;141(9):1060-1069. doi: 10.1182/blood.2022017612.
5
A machine-learning model for reducing misdiagnosis in heparin-induced thrombocytopenia: A prospective, multicenter, observational study.一种用于减少肝素诱导的血小板减少症误诊的机器学习模型:一项前瞻性、多中心、观察性研究。
EClinicalMedicine. 2022 Nov 24;55:101745. doi: 10.1016/j.eclinm.2022.101745. eCollection 2023 Jan.
6
NETosis and thrombosis in vaccine-induced immune thrombotic thrombocytopenia.疫苗诱导免疫性血栓性血小板减少症中的 NETosis 和血栓形成。
Nat Commun. 2022 Sep 5;13(1):5206. doi: 10.1038/s41467-022-32946-1.
7
Explaining COVID-19 postvaccination-related immune thrombotic thrombocytopenia: a hypothesis-generating approach.解释 COVID-19 疫苗接种后相关免疫性血栓性血小板减少症:一种生成假说的方法。
Hum Vaccin Immunother. 2022 Nov 30;18(5):2050654. doi: 10.1080/21645515.2022.2050654. Epub 2022 Apr 12.
8
Scientific premise for the involvement of neutrophil extracellular traps (NETs) in vaccine-induced thrombotic thrombocytopenia (VITT).中性粒细胞胞外诱捕网(NETs)参与疫苗诱导的血栓性血小板减少症(VITT)的科学前提。
J Leukoc Biol. 2022 Mar;111(3):725-734. doi: 10.1002/JLB.5COVR0621-320RR. Epub 2021 Sep 1.
9
Atorvastatin improves bone marrow endothelial progenitor cell function from patients with immune-related hemocytopenia.阿托伐他汀可改善免疫相关性血细胞减少症患者的骨髓内皮祖细胞功能。
Ann Transl Med. 2021 Jul;9(14):1142. doi: 10.21037/atm-21-2459.
10
Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia.识别疫苗诱导的免疫性血栓性血小板减少症。
Crit Care Med. 2022 Jan 1;50(1):e80-e86. doi: 10.1097/CCM.0000000000005211.